Maintenance of the remission stage of Crohn's disease with adalimumab therapy during pregnancy

Intern Med. 2013;52(10):1049-53. doi: 10.2169/internalmedicine.52.9466. Epub 2013 May 15.

Abstract

A 25-year-old pregnant woman complained of abdominal pain and diarrhea. Total colonoscopy provided a diagnosis of Crohn's disease (CD) of the large intestine (Crohn's colitis). Because the patient was allergic to mesalazine, adalimumab (ADA) was used as maintenance therapy during pregnancy, following prednisolone as remission induction therapy. Remission of the patient's CD was maintained with ADA, and the patient delivered a baby girl without any difficulties. Remission of the patient's CD continued to be maintained with the administration of ADA after childbirth. We believe that this is the first report of the use of ADA therapy in a pregnant CD patient in Japan.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Blood Component Removal
  • Colonoscopy
  • Combined Modality Therapy
  • Crohn Disease / blood
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Crohn Disease / therapy
  • Drug Hypersensitivity / etiology
  • Female
  • Fetus / drug effects
  • Humans
  • Maintenance Chemotherapy
  • Mesalamine / adverse effects
  • Mesalamine / therapeutic use
  • Prednisolone / therapeutic use
  • Pregnancy
  • Pregnancy Complications / blood
  • Pregnancy Complications / diagnosis
  • Pregnancy Complications / drug therapy*
  • Pregnancy Complications / therapy
  • Remission Induction

Substances

  • Antibodies, Monoclonal, Humanized
  • Mesalamine
  • Prednisolone
  • Adalimumab